Tocilizumab: Difference between revisions
(Created page with "==Administration== *Type: IL-6 antagonist *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ==...") |
|||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[COVID]]=== | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Revision as of 20:46, 18 January 2022
Administration
- Type: IL-6 antagonist
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
COVID
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Trials show that may improved survival and other clinical outcomes in patients in admitted severe disease